SCHEMBL22378705

SCHEMBL22378705

N#Cc1cccc(-c2cccc(-c3cccc(-n4c5ccccc5c5ccccc54)c3C#N)c2)c1-n1c2ccccc2c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
HIF1A Q16665 1/20 0.44
CYP19A1 P11511 1/20 0.36
GABRA1 P14867 5/20 0.34
GABRG2 P18507 5/20 0.34
GABRB3 P28472 5/20 0.34
GABRA2 P47869 4/20 0.34
GABRA5 P31644 3/20 0.34
GABRA3 P34903 3/20 0.34
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
USP30 Q70CQ3 1/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
IMPDH2 P12268 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24830756 0.92 SMN1; SMN2 (0.43) SMN1; SMN2HIF1AALDH1A1KDM4EMEN1
SCHEMBL22379032 0.92 SMN1; SMN2 (0.39) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2
SCHEMBL22378236 0.92 SMN1; SMN2 (0.39) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2
SCHEMBL19755260 0.88 SMN1; SMN2 (0.43) SMN1; SMN2HIF1AALDH1A1KDM4EMEN1
SCHEMBL22378726 0.88 SMN1; SMN2 (0.37) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2
SCHEMBL22378618 0.88 SMN1; SMN2 (0.44) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2
SCHEMBL22378361 0.88 TRPA1 (0.34) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2
SCHEMBL22377480 0.87 SMN1; SMN2 (0.42) SMN1; SMN2HIF1AALDH1A1KDM4EMEN1
SCHEMBL22379431 0.87 SMN1; SMN2 (0.40) SMN1; SMN2HIF1AALDH1A1KDM4EPDCD1
SCHEMBL22377579 0.86 SMN1; SMN2 (0.43) SMN1; SMN2HIF1ACYP19A1GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-10-24 US disclosed
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CYP1A1, CRY2 SMN1; SMN2 3839/4885HIF1A 844/4885CYP19A1 20/4885
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same CRY1, CYP1A1, CRY2 SMN1; SMN2 3839/4885HIF1A 844/4885CYP19A1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.